Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
20
Recruiting, any sponsor type, condition "paroxysmal nocturnal hemoglobinuria"
By trial status
The same filters, counted in each status. Pick one to switch.
20 trials
Showing 1 to 20, recently updated first.
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05744921 · 202 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 10, 2028
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Curitiba, Brazil; São Paulo, Brazil; Toronto, Canada · 50 sites in all
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT03520647 · 56 participants (planned) · Start Feb 19, 2019 · Primary completion Jun 1, 2027
Drug: Cyclophosphamide · For: Severe Aplastic Anemia (SAA); Hypo-Plastic Myelodysplastic Syndrome (MDS); Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Bethesda, Maryland
Zhuhai United Laboratories Co., Ltd.Industry
NCT07760467 · 94 participants (planned) · Start Aug 26, 2026 · Primary completion May 8, 2027
Drug: Part1: TUL321; Part1: Placebo and 2 more · For: Paroxysmal Nocturnal Hemoglobinuria, PNH
Sites: Changsha, China
- Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06934967 · 12 participants (planned) · Start Oct 28, 2025 · Primary completion Oct 14, 2031
Drug: LNP023 · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Atlanta, Georgia; New Brunswick, New Jersey; Philadelphia, Pennsylvania · 15 sites in all
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07154745 · 35 participants (planned) · Start Jun 11, 2026 · Primary completion Jan 18, 2030
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Ribeirão Preto, Brazil; Santo André, Brazil; São Paulo, Brazil · 20 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07187401 · 24 participants (planned) · Start Feb 11, 2026 · Primary completion Nov 29, 2029
Drug: ALN-CFB; Placebo · For: Paroxysmal Nocturnal Hemoglobinuria (PNH); Persistent Anemia
Sites: Toronto, Canada; Suwon, South Korea; Seoul, South Korea · 8 sites in all
- A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Recruiting
Apellis Pharmaceuticals, Inc.Industry
NCT04901936 · 12 participants (planned) · Start Feb 4, 2021 · Primary completion Dec 2028
Drug: Pegcetacoplan · For: Paroxysmal Nocturnal Hemoglobinuria (PNH); Paroxysmal Hemoglobinuria
Sites: Atlanta, Georgia; Prague, Czechia; Paris, France · 12 sites in all
ADARx Pharmaceuticals, Inc.Industry
NCT05876312 · 50 participants (planned) · Start Aug 7, 2023 · Primary completion Mar 31, 2028
Drug: ADX-038; Placebo · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Brisbane, Australia; Melbourne, Australia; Parkville, Australia · 4 sites in all
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT06412497 · 60 participants (planned) · Start Jun 5, 2024 · Primary completion May 1, 2035
Drug: Rituximab; Rabbit ATG and 6 more · For: Severe Aplastic Anemia; Acquired Amegakaryocytic Thrombocytopenia; Acquired Pure Red Cell Aplasia and 1 more
Sites: Minneapolis, Minnesota
Novartis PharmaceuticalsNovartis (NVS)
NCT06931691 · 80 participants (planned) · Start Jun 10, 2025 · Primary completion Apr 21, 2027
Drug: LNP023 · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Hefei, China; Guangzhou, China; Shijiazhuang, China · 14 sites in all
Shanghai Lanyi Therapeutics Co., Ltd.Industry
NCT07256301 · 24 participants (planned) · Start Jan 3, 2024 · Primary completion Aug 31, 2026
Drug: EA5 · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China; Hangzhou, China
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06312644 · 75 participants (planned) · Start Dec 16, 2024 · Primary completion Jul 11, 2034
Drug: Ultomiris · For: Ultomiris-exposed Pregnant/ Postpartum; Pregnancy; Paroxysmal Nocturnal Hemoglobinuria (PNH) and 3 more
Sites: Boston, Massachusetts; Melbourne, Australia; Paris, France · 7 sites in all
- Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07470762 · 50 participants (planned) · Start Feb 14, 2026 · Primary completion May 30, 2027
Drug: HS-10542; HS-10542 and 1 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Hangzhou, China
Shenzhen Kangzhe Biotechnology Co., Ltd.Industry
NCT07462780 · 88 participants (planned) · Start Mar 5, 2026 · Primary completion Nov 2026
Drug: CMS-D017 Capsule; CMS-D017 Placebo Capsule and 2 more · For: Paroxysmal Nocturnal Hemoglobinuria, PNH; Complement-mediated Kidney Disease
Sites: Beijing, China
- Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular HemolysisPivotal-lookingRecruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06449001 · 6 participants (planned) · Start Aug 11, 2025 · Primary completion May 28, 2027
Drug: Danicopan · For: Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis
Sites: Saskatoon, Canada; Paris, France; Leeds, United Kingdom · 4 sites in all
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07152288 · 24 participants (planned) · Start May 29, 2025 · Primary completion Sep 2025
Drug: HSK39297 tablets; HSK39297 tablets and 1 more · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Beijing, China
- Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentPivotal-lookingRecruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06932471 · 20 participants (planned) · Start Aug 30, 2024 · Primary completion Dec 30, 2025
Drug: MY008211A tablets · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Beijing, China
- Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyPivotal-lookingRecruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06932744 · 66 participants (planned) · Start Aug 30, 2024 · Primary completion Dec 30, 2025
Drug: MY008211A tablets; Eculizumab Injection · For: Paroxysmal Nocturnal Haemoglobinuria (PNH)
Sites: Beijing, China; Tianjin, China
- Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal HemoglobinuriaPivotal-lookingRecruiting
Wuhan Createrna Science and Technology Co., LtdIndustry
NCT06933914 · 120 participants (planned) · Start Nov 30, 2024 · Primary completion Dec 30, 2026
Drug: MY008211A tablets · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Tianjin, China
- Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06745622 · 47 participants (planned) · Start Jan 3, 2025 · Primary completion Jun 2027
Drug: HSK39297 tablets · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Nanjing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.